Sanofi Price Chart
Sanofi SAN1N.MX Financial and Trading Overview
Sanofi stock price | 1629.2 MXN |
Previous Close | 1769.71 MXN |
Open | 0 MXN |
Bid | 0 MXN x N/A |
Ask | 0 MXN x N/A |
Day's Range | 0 - 0 MXN |
52 Week Range | 0 - 2105.02 MXN |
Volume | 0 MXN |
Avg. Volume | 333 MXN |
Market Cap | N/A |
Beta (5Y Monthly) | 0.416091 |
PE Ratio (TTM) | 15.714273 |
EPS (TTM) | 112.62 MXN |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
SAN1N.MX Valuation Measures
Enterprise Value | 2.22T MXN |
Trailing P/E | 15.714273 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 29.642887 |
Enterprise Value/Revenue | 48.022 |
Enterprise Value/EBITDA | 154.127 |
Trading Information
Sanofi Stock Price History
Beta (5Y Monthly) | 0.416091 |
52-Week Change | -13.48% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2105.02 MXN |
52 Week Low | 0 MXN |
50-Day Moving Average | 1794.86 MXN |
200-Day Moving Average | 1794.86 MXN |
SAN1N.MX Share Statistics
Avg. Volume (3 month) | 333 MXN |
Avg. Daily Volume (10-Days) | 458 MXN |
Shares Outstanding | N/A |
Float | 1.1B |
Short Ratio | N/A |
% Held by Insiders | 11.39% |
% Held by Institutions | 43.73% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 18.08% |
Operating Margin (ttm) | 24.42% |
Gross Margin | 69.93% |
EBITDA Margin | 31.15% |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 46.2B MXN |
Revenue Per Share (ttm) | 36.9 MXN |
Quarterly Revenue Growth (yoy) | 8.09% |
Gross Profit (ttm) | 31.7B MXN |
EBITDA | 14.39B MXN |
Net Income Avi to Common (ttm) | 8.36B MXN |
Diluted EPS (ttm) | 112.618 |
Quarterly Earnings Growth (yoy) | -0.70% |
Balance Sheet
Total Cash (mrq) | 12.74B MXN |
Total Cash Per Share (mrq) | 10.2 MXN |
Total Debt (mrq) | 21.21B MXN |
Total Debt/Equity (mrq) | 28.23 MXN |
Current Ratio (mrq) | N/A |
Book Value Per Share (mrq) | 59.701 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of Sanofi
Country | Mexico |
State | N/A |
City | Paris |
Address | 46, avenue de la Grande Arm e |
ZIP | 75017 |
Phone | 33 1 53 77 40 00 |
Website | https://www.sanofi.com |
Industry | |
Sector(s) | |
Full Time Employees | 91573 |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Q&A For Sanofi Stock
What is a current SAN1N.MX stock price?
Sanofi SAN1N.MX stock price today per share is 1629.2 MXN.
How to purchase Sanofi stock?
You can buy SAN1N.MX shares on the Mexico exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sanofi?
The stock symbol or ticker of Sanofi is SAN1N.MX.
How many shares does Sanofi have in circulation?
The max supply of Sanofi shares is 0.
What is Sanofi Price to Earnings Ratio (PE Ratio)?
Sanofi PE Ratio is 14.46660400 now.
What was Sanofi earnings per share over the trailing 12 months (TTM)?
Sanofi EPS is 112.62 MXN over the trailing 12 months.